PDLI Financial Facts
Net income per basic share (in dollars per share): 0.08License and other: -127K
See Full Income Statement
Accrued liabilities: 9.48M
Commitments and contingencies (Note 13): 0
See Full Balance Sheet
PDL BioPharma, Inc. (PDLI) Earnings
|
Expand Research on PDLI
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -577.5% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -7.3% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3/8/18 |  |
Q417 | $0.15 | $0.03 | +$0.12 | $68M | $45.3M | = |  | | Details |
| 8/3/17 | |
Q217 | $0.39 | N/A | N/A | $143.8M | $21M | = | | | Details |
8/7/19  |
|
Q219 | N/A | $0.04 | N/A | N/A | $31.74M | N/A | N/A | N/A | |
| 5/7/20 | |
Q120 | -$0.26 | $0.05 | -$0.31 | $6M | $37.62M | N/A | | | Details |
| 11/6/19 | |
Q319 | -$0.16 | $0.05 | -$0.21 | $44.2M | $33.86M | N/A | | | Details |
| 3/11/20 | |
Q419 | -$0.48 | $0.05 | -$0.53 | N/A | $37.7M | N/A | | | Details |
| 5/3/17 | |
Q117 | $0.04 | $0.05 | -$0.01 | $45.4M | $50.23M | = | | | Details |
| 8/8/18 | |
Q218 | -$0.76 | N/A | N/A | $46.6M | $44.66M | N/A | | | Details |
